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OBJECTIVE — To determine the effect of total parenteral nutrition (TPN)-induced hyper-
glycemia on hospital outcome.
RESEARCH DESIGN AND METHODS — The study determined whether blood glu-
cose values before, within 24 h, and during days 2–10 of TPN are predictive of hospital com-
plications and mortality.
RESULTS — Subjects included a total of 276 patients receiving TPN for a mean duration of
15  24 days (SD). In multiple regression models adjusted for age, sex, and diabetes status,
mortality was independently predicted by pre-TPN blood glucose of 121–150 mg/dl (odds ratio
[OR] 2.2, 95% CI 1.1–4.4, P  0.030), 151–180 mg/dl (3.41, 1.3–8.7, P  0.01), and 180
mg/dl(2.2,0.9–5.2,P0.077)andbybloodglucosewithin24hof180mg/dl(2.8,1.2–6.8,
P  0.020). A blood glucose within 24 h of 180 mg/dl was associated with increased risk of
pneumonia (OR 3.1, 95% CI 1.4–7.1) and acute renal failure (2.3, 1.1–5.0).
CONCLUSIONS — Hyperglycemia is associated with increased hospital complications and
mortality in patients receiving TPN.
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T
he beneﬁcial effect of total paren-
teral nutrition (TPN) in improving
the nutrition status of hospitalized
malnourished patients is well established
(1). Recent randomized trials and meta-
analyses, however, have raised questions
about its safety and the increased rate of
TPN-associated complications and mor-
tality in critically ill patients (2–4). The
increased risk of complications during
TPN therapy can be related, among other
factors, to the development of hypergly-
cemia, which occurs in 10–88% of hos-
pitalized patients receiving TPN therapy
(4–6). Despite the high frequency of
TPN-induced hyperglycemia, it is not
known if the severity of hyperglycemia
and/or the timing of hyperglycemia be-
foreinitiationorduringTPNtherapylead
to hospital complications. Accordingly,
we determined 1) the impact of TPN-
inducedhyperglycemiaonsurvivaland2)
whether blood glucose value before,
shortly after initiation (within 24 h),
and/or during TPN therapy can serve as
predictive markers of in-hospital compli-
cations and mortality.
RESEARCH DESIGN AND
METHODS— Thisworkinvolvedret-
rospective study of medical and surgical
patients receiving TPN during the period
of 1 January 2006 to 31 December 2006
at Grady Memorial Hospital in Atlanta,
Georgia. Patients were managed after the
hospital TPN nutrition protocol aimed to
provide 25–35 kcal   kg
1   day
1 and
1–2gprotein kg
1 day
1.Wecollected
information on demographics; blood glu-
coseonadmission,pre-TPN,within24h,
and during days 2–10 of TPN; Acute
Physiology and Chronic Health Evalua-
tion(APACHE)IIscore;lengthofhospital
stay; hospital complications; and
mortality.
Data analysis
Forcomparisonofbaselinedemographics
and clinical characteristics between
groups, we used two-sample Wilcoxon’s
tests for continuous variables and 
2 test
for categorical variables with Bonferroni’s
corrections when applicable. Multiple lo-
gistic regression and adjusted odds ratios
(ORs) were used to determine the inﬂu-
ence of clinical characteristics on mortal-
ity and complications. A P value of 0.05
was considered signiﬁcant.
RESULTS— The study population in-
cluded 276 consecutive medical (33%)
and surgical (65%) patients (mean age
5118years,BMI267kg/m
2,known
diabetes 19.2%, intensive care unit ad-
mission78.2%).TPNwasstarted1212
days after admission and was given for a
mean duration of 15  24 days.
The mean blood glucose level on ad-
mission was 139  85 mg/dl. The mean
blood glucose level before TPN was
123.2  33 mg/dl and increased to a
mean blood glucose of 146  44 mg/dl
within 24 h of TPN and remained ele-
vated(14740mg/dl)duringdays2–10
ofTPNinfusion(P0.01frombaseline).
The overall hospital mortality was
27.2%. Deceased patients were older,
were more likely to be in the intensive
care unit, and had higher admission
APACHE II scores versus nondeceased
patients(all,P0.01).Deceasedpatients
had a higher pre-TPN blood glucose
(12937vs.12132mg/dl,P0.08),
a higher blood glucose within 24 h
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0.003),andahigherbloodglucoseduring
days2–10ofTPN(16153vs.14234
mg/dl, P  0.013) than nondeceased
patients.
In multiple regression models ad-
justedforage,sex,andhistoryofdiabetes,
the likelihood of death was indepen-
dently predicted by elevated pre-TPN
blood glucose between 121 and 150
mg/dl (OR 2.2, 95% CI 1.1–4.4, P 
0.030), 151 and 180 mg/dl (3.41, 1.3–
8.7, P  0.010), and 180 mg/dl (2.2,
0.9–5.2, P  0.077) or by the blood glu-
cose within 24 h 180 mg/dl (2.8, 1.2–
6.8, P  0.020) versus patients with a
meanbloodglucose120mg/dl.Inmul-
tivariate analysis adjusting for age, sex,
and history of diabetes, the blood glucose
within 24 h of TPN 180 mg/dl was as-
sociated with increased risk of pneumo-
nia (OR 3.6, 95% CI 1.6–8.4) and acute
renal failure (2.2, 1.02–4.8 1) compared
with patients with blood glucose 120
mg/dl. Patients with higher blood glucose
levels during TPN had a longer hospital
(P  0.011) and intensive care unit (P 
0.008) length of stay.
CONCLUSIONS — Malnutrition is
reported in up to 40% of critically ill pa-
tients (1,7) and is associated with in-
creased risk of hospital complications,
longer hospital stay, and mortality (8).
Despite improving the nutrition state and
immunologic competence (9), TPN ther-
apy has been associated with increased
risk for infections and mortality (2,10–
13). The increased risk of complications
appears to be related, among other fac-
tors, to the development of hyperglyce-
mia (4,14). Observational studies have
reported a 33% mortality rate in TPN pa-
tients who developed hyperglycemia
(15),aswellasanincreasedriskofcardiac
complications, infections, systemic sep-
sis, and acute renal failure (3,4,6). In
agreement with these reports, we found a
strong correlation between TPN-induced
hyperglycemia and poor clinical out-
come.Ofinterest,weobservedthatvalues
before and within 24 h of initiation of
TPNarebetterpredictorsofhospitalmor-
tality and complications than blood glu-
cose during the entire duration of TPN
(Fig. 1).
In multiple regression models ad-
justed for age, sex, and diabetes status,
mortalitywasindependentlypredictedby
pre-TPN blood glucose values between
151 and 180 mg/dl (OR 3.41, 95% CI
1.3–8.7,P0.01)and180mg/dl(2.2,
0.9–5.2, P  0.077), as well as by blood
glucose within 24 h of TPN 180 mg/dl
(2.8, 1.2–6.8, P  0.020) versus patients
without hyperglycemia. In addition,
blood glucose 180 mg/dl within 24 h of
initiation of TPN was associated with in-
creased risk of pneumonia (3.1, 1.4–7.1)
and acute renal failure (2.3, 1.1–5.0).
The mechanisms underlying the det-
rimentaleffectsofhyperglycemiarelateto
alterations in immune functions and in-
ﬂammatory response (16,17). Hypergly-
cemia impairs leukocyte function,
phagocytosis, and chemotaxis (18). Hy-
perglycemiaalsoincreasescounterregula-
tory hormones, inﬂammatory cytokines,
and oxidative stress (16,17), which can
lead to endothelial dysfunction and car-
diovascular complications (17). In addi-
tion to hyperglycemia, the administration
ofIntralipidinTPNsolutionsmayworsen
clinical outcome. Intralipid infusion, a
soybean oil-based emulsion rich in n-6
polyunsaturatedfattyacids(19),hasbeen
associated with exaggerated inﬂamma-
toryresponse,immunosuppression,insu-
lin resistance, increased blood pressure,
endothelial dysfunction, and oxidative
stress (19).
In summary, TPN-induced hypergly-
cemia is associated with increased length
of hospital stay, increased risk of compli-
cations, and higher mortality in hospital-
ized patients. Our study indicates that
blood glucose values before and within
24 h of initiation of TPN are better pre-
dictors of hospital mortality and compli-
cations than the mean blood glucose
during the entire duration of TPN. These
results suggest that early and aggressive
intervention to prevent and correct hy-
perglycemia may improve clinical out-
come in patients receiving TPN.
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